Thomas Levato is a partner in Goodwin’s nationally recognized Life Sciences and Technology Companies practice groups. He has extensive experience representing investment banks, issuers and investors in capital markets transactions, including IPOs, follow-on public offerings, rights offerings and private placements of equity, equity-linked and debt securities. His practice covers a wide range of industries including life sciences, technology, cannabis, energy, cleantech, industrials, casino/gaming, media and retail/consumer goods.

Mr. Levato is a market leader in alternative financing transactions, including Confidentially Marketed Public Offerings (CMPOs), Registered Direct Offerings (RDs), Private Investments in Public Equity (PIPEs) and At-the-Market Offerings (ATMs). Goodwin is consistently ranked as one of the most active law firms in the United States advising on these transactions.

Mr. Levato advises life sciences companies as general outside counsel on a variety of transactions. He also routinely counsels clients on corporate governance matters and SEC compliance.  

Mr. Levato's experience includes executing capital markets transactions involving foreign issuers domiciled throughout Europe and in the United Kingdom, Canada and Israel.

A representative list of Mr. Levato’s recent life sciences capital markets transactions is set forth below:

  • Merrill Lynch, Leerink and Stifel in a $312.0 million follow-on public offering for Zogenix, Inc.
  • Morgan Stanley, Cowen and Jefferies in a $276.0 million follow-on public offering for Immunomedics, Inc.  
  • Merrill Lynch and Cowen in the $35.6 million U.S. IPO for TiGenix NV.
  • Leerink and Cowen in the $60.0 million IPO for Bellerophon Therapeutics, Inc.
  • Stifel and Piper Jaffray in the $66.0 million IPO for Conatus Pharmaceuticals Inc.
  • Piper Jaffray and Stifel in the $58.5 million U.S. IPO for Innocoll AG.
  • Stifel and JMP Securities in the $45.0 million IPO for Marinus Pharmaceuticals, Inc.
  • Roth Capital Partners in a €13.0 million U.S. private placement for Oryzon Genomics, S.A. 
  • J.P. Morgan and Morgan Stanley in an $87.1 million follow-on public offering for NPS Pharmaceuticals, Inc.
  • Leerink and Cowen in a $47.6 million U.S. follow-on public offering for Trillium Therapeutics Inc.
  • Leerink and RBC Capital Markets in a $151.8 million U.S. follow-on public offering for Tekmira Pharmaceuticals Corporation
  • Stifel in a $35.0 million U.S. private placement for Strongbridge Biopharma plc  
  • Medicrea International in a €20.0 million U.S. private placement
  • Canaccord Genuity and JMP Securities in a $17.5 million U.S. follow-on public offering for Summit Therapeutics plc.
  • Canaccord Genuity in a $37.4 million U.S. follow-on public offering and concurrent $32.7 million U.S. private placement for Neovasc Inc.
  • Leerink and Cantor Fitzgerald in a $150.5 million U.S. follow-on public offering for Aurinia Pharmaceuticals Inc.
  • Jefferies in a $63.0 million U.S. follow-on public offering for Compugen Ltd.
  • BMO Capital Markets and Canaccord Genuity in a $42.7 million U.S follow-on public offering for VBI Vaccines Inc.
  • Canaccord Genuity in a $50.3 million U.S. follow-on public offering for Novadaq Technologies Inc.
  • Baker Bros. Advisors, a life sciences focused hedge fund, as lead investor in numerous public and private portfolio company investments

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2000
The George Washington University Law School

(with honors)

B.A., 1995
Bucknell University

Admissions

Bar

New York
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师